- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- Interventions
- dexamethasone, doxorubicin hydrochloride, thalidomide
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2006
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 433–456
of 617
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Endometrial Cancer
- Interventions
- pegylated liposomal doxorubicin hydrochloride
- Drug
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 10
- States / cities
- Orange, California • Indianapolis, Indiana • Iowa City, Iowa + 7 more
- Conditions
- Breast Cancer
- Interventions
- filgrastim, CAF regimen, carboplatin, cisplatin, cyclophosphamide, doxorubicin hydrochloride, fluorouracil, ifosfamide, melphalan, paclitaxel, thiotepa, peripheral blood stem cell transplantation, samarium Sm 153 lexidronam pentasodium
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Louisiana State University Health Sciences Center Shreveport
- Other
- Eligibility
- 21 Years to 65 Years · Female only
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2001
- U.S. locations
- 1
- States / cities
- Shreveport, Louisiana
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
- Interventions
- aldesleukin, filgrastim, therapeutic allogeneic lymphocytes, cyclophosphamide, etoposide, pegylated liposomal doxorubicin hydrochloride
- Biological · Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Stage III Uterine Corpus Cancer, Stage IV Uterine Corpus Cancer
- Interventions
- Doxorubicin Hydrochloride, Cisplatin, Radiation Therapy
- Drug · Radiation
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Kidney Cancer
- Interventions
- dactinomycin, filgrastim, cyclophosphamide, doxorubicin hydrochloride, etoposide, vincristine sulfate, conventional surgery, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 0 Years to 15 Years
- Enrollment
- 3,031 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2003
- U.S. locations
- 206
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more
- Conditions
- Lymphoma
- Interventions
- doxorubicin hydrochloride, vinblastine, standard subtotal nodal irradiation
- Drug · Radiation
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 16 Years and older
- Enrollment
- 348 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1992 – 2014
- U.S. locations
- 22
- States / cities
- La Jolla, California • Wilmington, Delaware • Washington D.C., District of Columbia + 18 more
- Conditions
- Sarcoma
- Interventions
- filgrastim, cisplatin, doxorubicin hydrochloride, ifosfamide, melphalan, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 10 Years to 55 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1994 – 2014
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Breast Cancer
- Interventions
- cyclophosphamide, doxorubicin hydrochloride, conventional surgery, neoadjuvant therapy, thermal ablation therapy
- Drug · Procedure
- Lead sponsor
- Imunon
- Industry
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Orange, California • Coral Springs, Florida + 4 more
- Conditions
- Sarcoma
- Interventions
- filgrastim, cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, vincristine sulfate, adjuvant therapy, conventional surgery, neoadjuvant therapy, brachytherapy, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 0 Years to 50 Years
- Enrollment
- 587 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2023
- U.S. locations
- 212
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 155 more
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- Interventions
- bortezomib, dexamethasone, pegylated liposomal doxorubicin hydrochloride, thalidomide
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Lymphoma
- Interventions
- AMG 531, Rituximab, Cyclophosphamide, Vincristine, Doxorubicin, Dexamethasone, Methotrexate, Cytarabine, Placebo
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Lymphoma
- Interventions
- Duvelisib, Rituximab, R-CHOP, Prednisone
- Drug
- Lead sponsor
- SecuraBio
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Prostate Cancer
- Interventions
- pegylated liposomal doxorubicin hydrochloride, hyperthermia treatment
- Drug · Procedure
- Lead sponsor
- Imunon
- Industry
- Eligibility
- 40 Years and older · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 2
- States / cities
- Shreveport, Louisiana • Myrtle Beach, South Carolina
- Conditions
- Fallopian Tube Cancer, Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer
- Interventions
- everolimus, carboplatin, pegylated liposomal doxorubicin hydrochloride, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2018
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Lymphoma
- Interventions
- Cyclophosphamide, Mesna, Vincristine, Methotrexate, Ara-C, Dexamethasone, G-CSF, Doxil
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2015
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Ovarian Cancer, Sarcoma
- Interventions
- cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, vincristine sulfate, adjuvant therapy, neoadjuvant therapy, therapeutic conventional surgery, brachytherapy, intraoperative radiation therapy, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1991 – 2013
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Breast Adenocarcinoma, Estrogen Receptor Positive, HER2/Neu Negative, Recurrent Breast Carcinoma, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
- Interventions
- Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel, Therapeutic Conventional Surgery, Triciribine Phosphate
- Drug · Other · Procedure
- Lead sponsor
- Prescient Therapeutics, Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2020
- U.S. locations
- 2
- States / cities
- Tampa, Florida • The Bronx, New York
- Conditions
- Advanced Adult Hepatocellular Carcinoma, Recurrent Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v7, Stage IIIA Hepatocellular Carcinoma AJCC v7, Stage IIIB Hepatocellular Carcinoma AJCC v7, Stage IIIC Hepatocellular Carcinoma AJCC v7, Stage IV Hepatocellular Carcinoma AJCC v7, Stage IVA Hepatocellular Carcinoma AJCC v7, Stage IVB Hepatocellular Carcinoma AJCC v7, Unresectable Hepatocellular Carcinoma
- Interventions
- Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Pharmacogenomic Study, Sorafenib Tosylate
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 356 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2018
- U.S. locations
- 659
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 404 more
- Conditions
- Metastatic Urothelial Carcinoma, Transitional Cell Carcinoma, Unresectable Transitional Cell Carcinoma
- Interventions
- Doxorubicin Hydrochloride, Gemcitabine Hydrochloride, Ixazomib Citrate
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Prostate Cancer
- Interventions
- pegylated liposomal doxorubicin hydrochloride
- Drug
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- Male only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2001
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Hodgkin Lymphoma
- Interventions
- Brentuximab vedotin, Doxorubicin Hydrochloride, Pembrolizumab, Dacarbazine
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Sarcoma
- Interventions
- cyclophosphamide, dexrazoxane hydrochloride, disaccharide tripeptide glycerol dipalmitoyl, doxorubicin hydrochloride, vincristine sulfate, surgical procedure, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 3 Years to 60 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2000
- U.S. locations
- 2
- States / cities
- New York, New York • Houston, Texas
- Conditions
- AIDS-related Diffuse Large Cell Lymphoma, AIDS-related Immunoblastic Large Cell Lymphoma, AIDS-related Peripheral/Systemic Lymphoma, AIDS-related Small Noncleaved Cell Lymphoma
- Interventions
- rituximab, etoposide, doxorubicin hydrochloride, vincristine sulfate, prednisone, cyclophosphamide, laboratory biomarker analysis
- Biological · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2009
- U.S. locations
- 1
- States / cities
- Rockville, Maryland